H. Lundbeck A/S

OTCPK:HLBB.F Stock Report

Market Cap: US$6.0b

H. Lundbeck Valuation

Is HLBB.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLBB.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLBB.F ($6.1) is trading below our estimate of fair value ($21.46)

Significantly Below Fair Value: HLBB.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLBB.F?

Key metric: As HLBB.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HLBB.F. This is calculated by dividing HLBB.F's market cap by their current earnings.
What is HLBB.F's PE Ratio?
PE Ratio16.5x
EarningsDKK 2.69b
Market CapDKK 42.66b

Price to Earnings Ratio vs Peers

How does HLBB.F's PE Ratio compare to its peers?

The above table shows the PE ratio for HLBB.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27x
JAZZ Jazz Pharmaceuticals
15.9x16.7%US$7.4b
CORT Corcept Therapeutics
38.7x41.0%US$5.4b
ELAN Elanco Animal Health
33.7x2.7%US$6.9b
PBH Prestige Consumer Healthcare
19.8x5.3%US$4.1b
HLBB.F H. Lundbeck
16.5x8.6%US$42.7b

Price-To-Earnings vs Peers: HLBB.F is good value based on its Price-To-Earnings Ratio (16.5x) compared to the peer average (27x).

Price to Earnings Ratio vs Industry

How does HLBB.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

9 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
3x-7.1%US$3.87b
NDOI Endo
0.6xn/aUS$1.91b
PROC Procaps Group
1.5xn/aUS$77.85m
KPRX Kiora Pharmaceuticals
1.9x-40.0%US$9.77m
HLBB.F 16.5xIndustry Avg. 19.1xNo. of Companies9PE01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HLBB.F is good value based on its Price-To-Earnings Ratio (16.5x) compared to the US Pharmaceuticals industry average (19.1x).

Price to Earnings Ratio vs Fair Ratio

What is HLBB.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLBB.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HLBB.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLBB.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$6.10
US$7.08
+16.0%
14.0%US$9.74US$6.00n/a11
Nov ’25n/a
US$7.13
0%
9.2%US$8.30US$6.19n/a11
Oct ’25n/a
US$6.85
0%
12.5%US$8.43US$5.18n/a12
Sep ’25US$7.13
US$6.83
-4.2%
12.0%US$8.55US$5.25n/a12
Aug ’25US$6.15
US$5.91
-3.9%
12.5%US$7.95US$5.06n/a12
Jul ’25n/a
US$5.82
0%
10.9%US$7.43US$5.10n/a12
Jun ’25US$5.40
US$5.82
+7.8%
10.9%US$7.43US$5.10n/a12
May ’25n/a
US$5.62
0%
12.3%US$7.26US$4.79n/a12
Apr ’25US$4.80
US$5.69
+18.6%
12.2%US$7.34US$4.84n/a12
Mar ’25US$4.75
US$5.52
+16.2%
12.5%US$7.20US$4.75n/a13
Feb ’25US$5.00
US$5.57
+11.3%
11.0%US$6.98US$4.80n/a13
Jan ’25n/a
US$5.57
0%
10.4%US$6.93US$4.76n/a13
Dec ’24US$4.80
US$5.66
+17.9%
10.8%US$7.00US$4.67n/a12
Nov ’24US$4.80
US$5.53
+15.2%
11.1%US$6.65US$4.53n/a11
Oct ’24n/a
US$5.42
0%
11.0%US$6.74US$4.59n/a11
Sep ’24n/a
US$5.45
0%
12.0%US$6.86US$4.38US$7.1312
Aug ’24n/a
US$5.48
0%
10.8%US$6.49US$4.43US$6.1512
Jul ’24n/a
US$5.41
0%
12.5%US$6.45US$4.40n/a12
Jun ’24US$5.07
US$5.41
+6.6%
12.5%US$6.45US$4.40US$5.4012
May ’24US$5.15
US$5.12
-0.6%
15.6%US$6.51US$4.44n/a12
Apr ’24n/a
US$4.80
0%
14.3%US$6.06US$3.85US$4.8012
Mar ’24US$4.24
US$4.78
+12.7%
14.2%US$6.08US$3.86US$4.7513
Feb ’24n/a
US$4.85
0%
15.2%US$6.28US$3.95US$5.0013
Jan ’24n/a
US$4.96
0%
18.6%US$6.48US$3.80n/a13
Dec ’23US$3.00
US$5.03
+67.5%
16.7%US$6.39US$3.75US$4.8013
Nov ’23US$3.60
US$4.99
+38.6%
15.5%US$6.09US$3.58US$4.8013

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.43

7D

-5.4%

1Y

73.9%

IQVIA Holdings

US$35.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$192.68

7D

-11.2%

1Y

-6.1%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$56.58

7D

-8.4%

1Y

10.3%